1 min read
Stipple Bio Announces Lilly Cancer Deal Valued at Up to $5.9 Billion
Stipple Bio announced the exclusive worldwide agreement on Nov. 16.

Stipple Bio announced Nov. 16 that it entered an exclusive worldwide oncology licensing agreement with Eli Lilly and Company.
The licensing deal is valued at up to $5.9 billion.
Stipple Bio is based in Cambridge, Massachusetts.